August 8, 2023
|
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
|
June 21, 2023
|
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
|
May 9, 2023
|
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
|
April 24, 2023
|
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
|
April 23, 2023
|
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
|
March 27, 2023
|
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
|
March 15, 2023
|
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
|
February 28, 2023
|
UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
|
February 15, 2023
|
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
|
February 9, 2023
|
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
|